Ab Initio Biotherapeutics Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$12M
Ab Initio Biotherapeutics General Information
Description
Developer of protein engineering platform designed for the discovery of therapeutic antibodies against difficult-to-access cellular targets. The company's platform allows for targeting multi-transmembrane and facilitates antibody generation relevant to a wide array of therapeutic indications including neurological, cardiovascular, endocrine and gastrointestinal disorders, enabling doctors to optimize the solubility and stability of drugs.
Contact Information
Website
www.aibio.comCorporate Office
- 280 Utah Avenue
- South San Francisco, CA 94080
- United States
Corporate Office
- 280 Utah Avenue
- South San Francisco, CA 94080
- United States
Ab Initio Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 23-Jul-2019 | $12M | Completed | Generating Revenue | ||
| 3. Corporate | 13-Dec-2016 | Completed | Startup | |||
| 2. Angel (individual) | $2M | $2M | Completed | Startup | ||
| 1. Accelerator/Incubator | 03-Mar-2015 | Completed | Startup |
Ab Initio Biotherapeutics Comparisons
Industry
Financing
Details
Ab Initio Biotherapeutics Competitors (32)
One of Ab Initio Biotherapeutics’s 32 competitors is CytomX Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Cytovance Biologics | Formerly PE-Backed | Oklahoma City, OK | ||||
| Aldevron | Formerly PE-Backed | Fargo, ND | ||||
| OncoResponse | Venture Capital-Backed | Houston, TX | ||||
| Renova Therapeutics | Venture Capital-Backed | Carlsbad, CA |
Ab Initio Biotherapeutics Patents
Ab Initio Biotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220220214-A1 | Apj modulators and uses thereof | Pending | 19-Jun-2019 | ||
| US-20200270324-A1 | Sirp polypeptide compositions and methods of use | Active | 18-May-2015 | ||
| ES-2857109-T3 | Sirp polypeptide compositions and methods of use | Active | 18-May-2015 | ||
| US-9845345-B2 | Sirp polypeptide compositions and methods of use | Active | 18-May-2015 | ||
| US-10774125-B2 | Sirp-gamma polypeptide compositions and methods of use | Active | 18-May-2015 | A61K38/1774 |
Ab Initio Biotherapeutics Former Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Pfizer (Pharmaceuticals) | Corporation | Minority | ||
| Polaris Partners | Venture Capital | Minority |
Ab Initio Biotherapeutics FAQs
-
When was Ab Initio Biotherapeutics founded?
Ab Initio Biotherapeutics was founded in 2015.
-
Where is Ab Initio Biotherapeutics headquartered?
Ab Initio Biotherapeutics is headquartered in South San Francisco, CA.
-
What industry is Ab Initio Biotherapeutics in?
Ab Initio Biotherapeutics’s primary industry is Biotechnology.
-
Is Ab Initio Biotherapeutics a private or public company?
Ab Initio Biotherapeutics is a Private company.
-
What is the current valuation of Ab Initio Biotherapeutics?
The current valuation of Ab Initio Biotherapeutics is .
-
What is Ab Initio Biotherapeutics’s current revenue?
The current revenue for Ab Initio Biotherapeutics is .
-
How much funding has Ab Initio Biotherapeutics raised over time?
Ab Initio Biotherapeutics has raised $2M.
-
Who are Ab Initio Biotherapeutics’s investors?
Pfizer (Pharmaceuticals) and Polaris Partners have invested in Ab Initio Biotherapeutics.
-
Who are Ab Initio Biotherapeutics’s competitors?
CytomX Therapeutics, Cytovance Biologics, Aldevron, OncoResponse, and Renova Therapeutics are some of the 32 competitors of Ab Initio Biotherapeutics.
-
When was Ab Initio Biotherapeutics acquired?
Ab Initio Biotherapeutics was acquired on 23-Jul-2019.
-
Who acquired Ab Initio Biotherapeutics?
Ab Initio Biotherapeutics was acquired by Ligand Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
